Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.

Yohei NoseYoshinori KagawaTaishi HataRyota MoriKenji KawaiAtsushi NaitoTakuya SakamotoKohei MurakamiYoshiteru KatsuraYoshiaki OhmuraToru MasuzawaAtsushi TakenoYutaka TakedaTakeshi KatoKohei Murata

Published in: Cancer chemotherapy and pharmacology (2020)

FTD/TPI plus BEV prolonged PFS and OS and had tolerable toxicity compared with FTD/TPI alone. CIN is an indicator of patients who will benefit from FTD/TPI plus BEV.

Keyphrases

metastatic colorectal cancer
oxidative stress
type diabetes
metabolic syndrome
adipose tissue